Comparison of the Effects of Nonfermented and Fermented Panax ginseng Root Against Hypertriglycemia in High-Fat Diet-Fed Mice

다국어 초록 (Multilingual Abstract)

Panax ginseng (P. ginseng C.A. Meyer, Araliaceae) is used as a therapeutic agent for various diseases. P. ginseng saponins, known as ginsenosides, are the main bioactive compounds responsible for its pharmacological activities. In this work, we have developed a new method of P. ginseng root processing termed solid-state fermentation and examined its effects compared with nonfermented P. ginseng. Mice were fed a high-fat diet (HFD) to induce hyperlipidemia and then received 100 mg·kg bw−1·day−1 of fermented or nonfermented P. ginseng orally for 3 weeks. We assessed the activities of lipogenic pathways and lipid levels in the liver and plasma. The administration of either nonfermented or fermented P. ginseng improved hepatic lipid transfer protein profiles. Nonfermented P. ginseng exhibited significant effects on the regulation of lipid synthesis and oxidation. However, apolipoprotein A4 (apoA4) expression was increased by the administration of fermented P. ginseng. When ginsenosides were analyzed by high-performance liquid chromatography (HPLC), the amounts of the ginsenosides, Rg2, Rc, Rh1(S), Rh1(R), and Rd, were increased by fermentation, with Rd becoming a major constituent of fermented P. ginseng. These findings imply that nonfermented P. ginseng improves hypertriglycemia in HFD-fed mice through regulation of the hepatic lipogenic pathway. In contrast, the effects of fermented P. ginseng were mediated through increased apoA4, leading to decreased triglycerides. The HPLC profiles of ginsenosides suggest that the compositional changes in P. ginseng caused by fermentation processing could be useful in the development of novel triglyceride-lowering therapies.

참고문헌 (Reference)

1 Yokozawa T, "Therapeutic potential of heat-processed Panax ginseng with respect to oxidative tissue damage" 1 : 30-44, 2007

2 주일우, "The Influence of Sam-Chil-Geun (Panax Notoginseng) on the Serum Lipid Levels and Inflammations of Rats with Hyperlipidemia Induced by Poloxamer-407" 연세대학교의과대학 51 (51): 504-510, 2010

3 Kang KS, "Study on the nitric oxide scavenging effects of ginseng and its compounds" 54 : 2558-2562, 2006

4 Matsuura H, "Study of red ginseng: New glucosides and a note on the occurrence of maltol" 32 : 4674-4677, 1984

5 Pandey A, "Solid-state fermentation" 13 : 81-84, 2003

6 Yamamoto M, "Serum HDL-cholesterol-increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man" 11 : 96-101, 1983

7 Kersten S, "Roles of PPARs in health and disease" 405 : 421-424, 2000

8 Duverger N, "Protection against atherogenesis in mice mediated by human apolipoprotein A-IV" 273 : 966-968, 1996

9 Barbier O, "Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis" 22 : 717-726, 2002

10 Yamamoto M, "Plasma lipid-lowering action of ginseng saponins and mechanism of the action" 11 : 84-87, 1983

11 Desvergne B, "Peroxisome proliferator-activated receptors: Nuclear control of metabolism" 20 : 649-688, 1999

12 Friedman M, "Nutritional consequences of food processing" 56 : 350-352, 2003

13 Goldberg IJ, "Lipoprotein apoC-II activation of lipoprotein lipase" 265 : 4266-4272, 1990

14 Kang KS, "Increase in the free radical scavenging activity of ginseng by heat-processing" 29 : 750-754, 2006

15 Yang JW, "Ginsenoside Rc promotes anti-adipogenic activity on 3T3-L1 adipocytes by down-regulating $C/EBP{\alpha}$ and $PPAR{\gamma}$" 20 : 1293-1303, 2015

16 Park S, "Ginsenoside $Rb_1$ and $Rg_1$ suppress triglyceride accumulation in 3T3-L1 adipocytes and enhance ${\beta}$-cell insulin secretion and viability in Min6 cells via PKA-dependent pathways" 72 : 2815-2823, 2008

17 Attele AS, "Ginseng pharmacology: Multiple constituents and multiple actions" 58 : 1685-1693, 1999

18 Zhang L, "Ginseng and obesity: Observations and understanding in cultured cells, animals and humans" 44 : 1-10, 2017

19 Sonnenborn U, "Ginseng (Panax ginseng C.A. Meyer)" 2 : 3-14, 1991

20 Park CH, "Evaluation of 7-O-galloyl-d-sedoheptulose, isolated from Corni Fructus, in the adipose tissue of type 2 diabetic db/db mice" 89 : 131-142, 2013

21 Sakakibara K, "Effect of ginseng saponins on cholesterol metabolism. I. The level and the synthesis of serum and liver cholesterol in rats treated ginsenosides" 23 : 1009-1016, 1975

22 Lopez-Miranda J, "Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism" 98 : 458-473, 2007

23 Sievenpiper JL, "Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans; the role of ginsenosides" 23 : 248-258, 2004

24 Amagase H, "Clarifying the real bioactive constituents of garlic" 136 : 716S-725S, 2006

25 Hikino H, "Changes of alkaloid composition and acute toxicity of Aconitum roots during processing" 97 : 359-366, 1977

26 Yun TK, "Brief introduction of Panax ginseng C.A. Meyer" 16 : S3-S5, 2001

27 Xiong Y, "Antiobesity and antihyperglycemic effects of ginsenoside $Rb_1$ in rats" 59 : 2505-2512, 2010

28 Yamamoto M, "Anti-atherogenic action of Panax ginseng in rats and in patients with hyperlipidemia" 45 : 149-, 1982

29 Steinmetz A, "Activation of lecithin: Cholesterol acyltransferase by human apolipoprotein A-IV" 260 : 2258-2264, 1985

30 Yahagi N, "Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in $Lep^{ob}/Lep^{ob}$ mice" 277 : 19353-19357, 2002

31 Folch J, "A simple method for the isolation and purification of total lipids from animal tissues" 226 : 497-509, 1957

32 Park JH, "A new processed ginseng with fortified activity" Korean Society of Ginseng 146-159, 1998